Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 61.33 CNY -5.5% Market Closed
Market Cap: 45.5B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

Net Margin
Hangzhou Tigermed Consulting Co Ltd

14.1%
Current
33%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
14.1%
=
Net Income
958.7m
/
Revenue
6.8B

Net Margin Across Competitors

Country CN
Market Cap 45.5B CNY
Net Margin
14%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.3B USD
Net Margin
14%
Country US
Market Cap 170.3B USD
Net Margin
18%
Country KR
Market Cap 66.5T KRW
Net Margin
24%
Country CH
Market Cap 37.6B CHF
Net Margin
9%
Country US
Market Cap 38.5B USD
Net Margin
22%
Country US
Market Cap 36.7B USD
Net Margin
9%
Country US
Market Cap 26.4B USD
Net Margin
21%
Country US
Market Cap 23B USD
Net Margin
17%
Country US
Market Cap 22.3B USD
Net Margin
-36%
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Market Cap
45.5B CNY
Industry
Life Sciences Tools & Services

Hangzhou Tigermed Consulting Co., Ltd. is a leading clinical trial and consulting organization based in China, dedicated to facilitating the development of innovative medical therapies. Founded in 2002, the company has rapidly ascended to prominence by leveraging its deep expertise in clinical research while providing comprehensive services that encompass all phases of clinical trials. With a robust portfolio that includes over 4,000 completed projects, Tigermed stands out for its strong focus on quality, efficiency, and regulatory compliance. Serving a diverse clientele of pharmaceutical and biotechnology companies, the firm positions itself as a vital partner in navigating the complexities of the drug development process, particularly in fast-growing Asian markets. An investor looking at Tigermed will find a company that is not only well-established but also poised for significant growth amidst rising global healthcare demands. With a strategic emphasis on expanding its geographic footprint and enhancing technological capabilities, Tigermed is capitalizing on the increasing investment in life sciences, particularly in China and surrounding regions. By harnessing big data analytics and innovative methodologies, the company is well-equipped to streamline clinical operations, reduce costs, and accelerate time-to-market for life-saving treatments. As the global healthcare landscape continues to evolve, Tigermed’s commitment to fostering advancements in clinical research places it in an advantageous position, making it an attractive prospect for investors seeking exposure in the burgeoning healthcare sector.

Intrinsic Value
70.64 CNY
Undervaluation 13%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
14.1%
=
Net Income
958.7m
/
Revenue
6.8B
What is the Net Margin of Hangzhou Tigermed Consulting Co Ltd?

Based on Hangzhou Tigermed Consulting Co Ltd's most recent financial statements, the company has Net Margin of 14.1%.